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Hemoglobin (Hb) C disorder is an important hemoglobinopathy with the highest endemicity in Middle 
East. The red blood cell abnormality is attributed to the beta thalassemic nature of the beta C (bC) globin 
gene. Here, a bioinformatic analysis was performed to study the effect of co-expression between human 
Hb C b-globin chain gene and U7.623. The gene ontological results show that full recovery of 
hemoglobin function and biological process can be derived. This confirms that U7 snRNA can be a 
good tool for gene therapy in Hb C disorder. 
 





Hemoglobinopathies are important groups of inherited 
disorders. Of several hemoglobinopathies, hemoglobin C 
disorder (beta 6, Glu-Val) is one of the most common 
forms (Ohba and Fujisawa, 1996). Similar to thalassemia 
carrier, heterozygous Hb C without concomitant thalasse-
mia is usually asymptomatic. It is noted that the mecha-
nism for the defective production of b C chains is a re-
duction of beta C mRNA (Reider, 1972). 
Recently, repair of defective splicing by small nuclear 
RNAs (SnRNAs) became a new approach in gene 
therapy for hemoglobinopathy. Utilization of snRNA as a 
therapeutic agent involves replacement of the natural 
antisense sequence with that targeted to the desired 
RNA (Gorman and Kole, 1999). It is anticipated that 
snRNAs as antisense carriers will allow for long term, 
possibly permanent, expression of RNA antisense to its 
targets such as the aberrant thalassemic splice sites in b-
globin RNA (Gorman and Kole, 1999). Here, a bioinfor-
matics analysis, specifically a gene ontology technique, 
was performed to study the effect of co-expression 
between human Hb C b-globin chain gene and U7.623.   
 
 
MATERIALS AND METHODS 
 
Getting the sequence  
 
The Pubmed database was used for data mining of the nucleic acid 
sequence for human b-globin chain. Then the mutation B6 was 
experimentally performed to derive primary sequence in 
hemoglobin C disorder. The modified U7 snRNA (U7.623) was also 
searched and used for the study. 
 
 
Prediction of the co-expression 
 
The prediction of molecular function and biological process for the 
combination between human Hb C b-globin chain gene and U7.623 
was performed using a novel gene ontology prediction tool, GoFig-
ure (Khan et al., 2003). GoFigure is a computational algorithm tool 
which is recently developed in gene ontology (Khan et al., 2003). 
The tool accepts an input DNA or protein sequence, and uses 
BLAST to identify homologous sequences in gene ontology 
annotated databases (Khan et al., 2003). The approach is to use a 
BLAST search to identify homologs in public databases that have 
been annotated with gene ontology terms (Khan et al., 2003). 
These include: SwissProt, Flybase (Drosophila), the Saccharomy-
ces Genome Database (SGD), Mouse Genome Informatics (MGI) 
and Wormbase (nematode) (Khan et al., 2003). The contents of the 
results will show results for molecular function as well as biological 
process of the studied protein (Khan et al., 2003). The prediction of 




RESULTS AND DISCUSSION 
 
Using GoFigure server, the molecular function and biolo-
gical process in the co-expression between human Hb C 
b-globin chain gene and U7.623 is predicted as seen in 
Table 1. 
 




Table 1. Molecular function and biological process due to the co-
expression between human Hb C b-globin chain gene and U7.623. 
 
Molecular function Biological process 







Figure 1. Expected biological process due to 
the co-expression between human Hb C b-








Hb C is an important hemoglobinopathy with the hig-
hest endemicity in Middle East. People with hemoglobin 
C disease usually have a mild hemolytic anemia and mild 
splenomegaly. Gene therapy is a new therapeutic 
highlight for many genetic diseases including to 
hemogloinopathy (Gorman and Kole, 1999). Concerning 
the thalassemia, modified U7 snRNA (Phillips and 
Turner, 1991) is a widely mentioned SnRNA for b-globin 
gene repair. U7.623, which is designed as antisense for 
the b-globin mutation in intron 2, is a snRNA might 
correct abnormal splicing in bC-globin gene.  
Here, the effect of co-expression between human Hb C 
b-globin chain gene and U7.623 was studied Figure 1. 
The gene ontological results show that full recovery of 
hemoglobin function and biological process can be 
derived.  Indeed, U7 snRNA, does prevent aberrant 
splicing and restores correct splicing resulting in 
increased synthesis of b C-mRNA and b C-globin. In 
addition, many lines of evidence from wet laboratories 
supporting the usefulness of the U7.623 antisense in 
repair of splicing and leading to increase in the amount of 
correctly spliced mRNA have been reported for several b-
thalassemia mutations (Gorman et al., 1998; Suter et al., 
1999; Suwanmanee et al., 2002). However, there is a 
limited knowledge on Hb C disorder. The result from this 
analysis can lead to the confirmation in the advantage of 
using of U7 snRNA gene antisense. That U7 snRNA can 
be a good tool for gene therapy in Hb C disorder is 
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